Alyftrek Ingredients and How the Triple Therapy Works
Alyftrek combines vanzacaftor and tezacaftor, which help more CFTR protein reach the cell surface, with deutivacaftor, which helps responsive CFTR channels stay open.
Timeline
- December 20, 2024: FDA approved Alyftrek for eligible patients age six and older with cystic fibrosis.
- Original indication: Eligibility required at least one F508del mutation or another CFTR mutation shown to respond.
- Pivotal program: Two 52-week noninferiority trials compared Alyftrek with elexacaftor, tezacaftor and ivacaftor.
Alyftrek is the brand name for a three-drug cystic-fibrosis therapy containing vanzacaftor, tezacaftor and deutivacaftor. FDA originally approved it on December 20, 2024 for people age six and older who have at least one F508del mutation or another mutation in the CFTR gene that responds to the treatment. It is taken by mouth once daily. [1][2]
Cystic fibrosis results from disease-causing variants in the CFTR gene. CFTR protein normally forms a channel that helps regulate chloride and water movement across cell surfaces. When too little functional protein reaches the surface or the channel does not work properly, thick secretions can affect the lungs, pancreas and other organs. [1]
Vanzacaftor and tezacaftor are called correctors. They help certain misprocessed CFTR protein fold and travel to the cell surface, increasing the amount available to function. Using two correctors targets different parts of the protein-processing problem. Their benefit still depends on the patient's mutation producing CFTR protein that can respond to this mechanism. [1][2]
Deutivacaftor is a potentiator. Once responsive CFTR channels reach the cell surface, it helps them stay open longer so chloride can move through more effectively. The three ingredients therefore address two linked limitations: the quantity of CFTR at the surface and the function of channels that arrive there. The therapy does not rewrite the underlying gene variant. [1][2]
FDA evaluated Alyftrek in two randomized, double-blind, 52-week phase 3 trials involving 971 participants. After a four-week run-in on elexacaftor, tezacaftor and ivacaftor, participants received that comparison therapy or Alyftrek. The primary outcome measured change in lung function through week 24, and the trials were designed to test whether Alyftrek was not unacceptably worse than the established regimen. [1]
The ingredient strengths and tablet count vary by age and weight, so a list of the adult trial doses is not a dosing instruction for every patient. The current label also covers food requirements, liver testing, interactions and adverse effects. Eligibility is mutation-specific, and a cystic-fibrosis clinician can confirm whether a laboratory or label list recognizes a particular CFTR variant. [1][2]
Alyftrek is called a CFTR modulator because it improves the behavior of a faulty protein rather than only treating downstream symptoms. Vanzacaftor and tezacaftor increase usable protein at the surface; deutivacaftor improves channel opening. That division of labor explains the triple combination, while the approved mutation list and individual clinical factors determine whether it is a suitable treatment. [1][2]